Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | PTGES | O14684 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.54 |
| ▸ | LOX | P28300 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13619724 | 0.84 | ALOX5 (0.47) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL24244869 | 0.78 | ALOX5 (0.43) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL9602556 | 0.77 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL9453079 | 0.76 | ALOX5 (0.58) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL5542170 | 0.76 | ALOX5 (0.57) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL14215435 | 0.75 | ALOX5 (0.54) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL16399862 | 0.74 | ALOX5 (0.55) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL1444769 | 0.74 | ALOX5 (0.55) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL2396906 | 0.74 | ALOX5 (0.76) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL15502039 | 0.74 | ALOX5 (0.76) | ALOX5CYP1A2PTGESLMNALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670176-B2 | Process for the preparation of zileuton | STRIDES SHASUN LIMITED (IN) | 2017-06-06 | — | — | US | claimed |
| US-20160376251-A1 | Process for the Preparation of Zileuton | STRIDES SHASUN LIMITED (IN) | 2016-12-29 | — | — | US | claimed |
| US-9670176-B2 | Process for the preparation of zileuton | STRIDES SHASUN LIMITED (IN) | 2017-06-06 | — | — | US | disclosed |
| US-9670176-B2 | Process for the preparation of zileuton | STRIDES SHASUN LIMITED (IN) | 2017-06-06 | — | — | US | disclosed |
| US-9670176-B2 | Process for the preparation of zileuton | STRIDES SHASUN LIMITED (IN) | 2017-06-06 | — | — | US | disclosed |
| US-9670176-B2 | Process for the preparation of zileuton | STRIDES SHASUN LIMITED (IN) | 2017-06-06 | — | — | US | disclosed |
| US-20160376251-A1 | Process for the Preparation of Zileuton | STRIDES SHASUN LIMITED (IN) | 2016-12-29 | — | — | US | disclosed |
| US-20160376251-A1 | Process for the Preparation of Zileuton | STRIDES SHASUN LIMITED (IN) | 2016-12-29 | — | — | US | disclosed |
| US-20160376251-A1 | Process for the Preparation of Zileuton | STRIDES SHASUN LIMITED (IN) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376251-A1 | Process for the Preparation of Zileuton | CYP2B6, UGT1A6, CYP2A6 | ALOX5 124/4885CYP1A2 35/4885PTGES 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.